Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
NCT ID: NCT00066196
Last Updated: 2008-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
110 participants
INTERVENTIONAL
2003-08-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma.
* To determine the safety of MEDI-522 ± DTIC in this patient population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
NCT00111696
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
NCT01993719
Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy
NCT00700167
Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma
NCT00203879
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
NCT03070392
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Integrin + Dacarbazine
Integrin + Dacarbazine
supplied in other formulations
1
MEDI-522
MEDI--522
IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MEDI--522
IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
Integrin + Dacarbazine
supplied in other formulations
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed, unresectable, Stage IV metastatic melanoma (AJCC staging), with at least one measurable lesion defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ³ 20 mm with conventional techniques or as ³ 10 mm with spiral computed tomography (CT) scan;
* Adult men and women of at least 18 years of age at the time of randomization;
* Women of reproductive potential (defined as being \<1 year post-menopausal) must have a negative serum β human chorionic gonadotropin (βhCG) pregnancy test within 3 days prior to randomization; and men and women of reproductive potential must agree to practice an effective method of avoiding pregnancy (including oral or implanted contraceptives, intrauterine device (IUD), condom, diaphragm with spermicide, cervical cap, abstinence, or sterile sexual partner) at the time the informed consent is signed, and must agree to continue using such precautions while receiving MEDI-522 and for 30 days after the final dose of MEDI-522;
* Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1;
* Life expectancy of at least 16 weeks;
* WBC ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, platelet count ≥ 100,000/mm3;
* Bilirubin ≤ 1.5 mg/dL, aspartate transaminase (AST)/alanine transaminase (ALT) ≤ 3 times upper limit of normal (ULN), serum creatinine ≤ 1.5 mg/dL, alkaline phosphatase ≤ 3.0 times ULN and prothrombin time (PT)/partial thromboplastin time (PTT) or international normalized ratio (INR) within normal range;
* Patients who have had prior treatment with adjuvant immunotherapy are eligible for study randomization provided that therapy ended at least 4 weeks prior to randomization;
* Patients who had prior surgery are eligible if at least 4 weeks have passed since their surgery;
* All toxicities related to prior adjuvant therapy must have resolved and all surgical wounds must have healed;
* Written informed consent and HIPAA authorization obtained from the patient prior to receipt of any study medication or beginning study procedures.
Exclusion
Patients must have none of the following at the time of randomization:
* Pregnancy or nursing;
* Prior therapy for metastatic melanoma including chemotherapy, radiotherapy, hormonal therapy, or biologics;
* Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancer;
* Current or planned participation (from the day of randomization through 30 days after the last dose of MEDI-522) in a research protocol in which an investigational agent or therapy may be administered;
* Received an investigational agent within 4 weeks prior to randomization;
* Known brain metastases or primary brain tumors, ocular melanoma, symptomatic pleural effusion or ascites requiring paracentesis;
* History of prior malignancies within the past 5 years other than non-melanomatous skin cancers that have been controlled, carcinoma in situ of the cervix, T1a or b prostate cancer noted incidentally during a transurethral resection of prostate (TURP) with prostate-specific antigen (PSA) values within normal limits since TURP, or superficial bladder cancer;
* History of pulmonary embolus.
* Any history or evidence of pulmonary embolism or thrombophlebitis (including deep vein thrombosis) requiring anticoagulant therapy (i.e., warfarin or heparin).
* Currently requiring therapeutic anticoagulation.
* Any evidence of hematemesis, melena, hematochezia, or gross hematuria;
* History or presence of bleeding diatheses;
* Elective surgery planned during the study period through 30 days after the last dose of MEDI-522.
* History of hypersensitivity to a previously administered monoclonal antibody.
* History of hypersensitivity to DTIC;
* History of immunodeficiency;
* Known human immunodeficiency virus (HIV) or known active viral hepatic infections;
* A prior myocardial infarction or angina, or uncontrolled/refractory hypertension within 6 months prior to randomization;
* A prior stroke or transient ischemic attack within the past 6 months;
* An active infection requiring systemic antiinfective therapy;
* Prior treatment with MEDI-522 or MEDI-523;
* A general medical or psychological condition or behavior, including substance dependence or abuse that, in the opinion of the investigator, might not permit the patient to complete the study or sign the informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedImmune LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MedImmune Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luz Hammershaimb, M.D.
Role: STUDY_DIRECTOR
MedImmune LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Pacific Shores Medical Group
Long Beach, California, United States
Saint Francis Memorial Hospital
San Francisco, California, United States
Cancer Institute Medical Group
Santa Monica, California, United States
Medical Group of North County
Vista, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
University of Miami
Miami, Florida, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Oncology Specialists, S.C.
Park Ridge, Illinois, United States
Indiana Oncology Hematology Consultants
Indianapolis, Indiana, United States
Indiana University Medical Center
Indianapolis, Indiana, United States
Johns Hopkins University - SKCC at Johns Hopkins
Lutherville, Maryland, United States
Boston Medical Center
Boston, Massachusetts, United States
Kansas City Oncology & Hematology Group
Kansas City, Missouri, United States
The Melanoma Center of St. Louis
St Louis, Missouri, United States
HemOnc Care, P.C.
Brooklyn, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
UNC-Chapel Hill
Chapel Hill, North Carolina, United States
Blumenthal Cancer Center
Charlotte, North Carolina, United States
Providence Portland Medical Center
Portland, Oregon, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Discovery Alliance
Houston, Texas, United States
The University of Texas, MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MI-CP095
Identifier Type: -
Identifier Source: org_study_id
NCT00081081
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.